NCT07073417

A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)

A Multicenter, Randomized, Open-label, Treatment Switching Phase II Study to Evaluate the Efficacy and Safety of XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 163 (actual)
• Sponsor: Hangzhou Sciwind Biosciences Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study is to compare the efficacy and safety of XW003 injection versus semaglutide injection in Chinese adults with obesity

Detailed description

In this Phase II study, eligible participants will be randomized into one of the two cohorts in a 1:1 ratio to receive once-weekly subcutaneous XW003 injection or semaglutide injection, including a dose-escalation period, a core treatment period and a treatment extension period, for up to 60 weeks.

Conditions

• Obesity
• Weight Management

Interventions

Type	Name	Description
DRUG	XW003 injection	Subcutaneous injection
DRUG	semaglutide injection	Subcutaneous injection

Timeline

• Start date: 2025-07-28
• Primary completion: 2027-02-27
• Completion: 2027-08-23
• First posted: 2025-07-18
• Last updated: 2026-04-13

Locations

1 site across 1 country: China